Skip to main content

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Análisis de la cuasispecie viral en la infección por virus de la hepatitis B: evolución natural yu asociada al tratamiento antiviral

IP: -
Collaborators: Maria Buti Ferret, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI09/00899
Duration: 01/01/2010 - 31/12/2012

Caracterización de perfiles proteómicos predictivos de hepatotoxicidad asociada a medicamentos antituberculosos: un estudio exploratorio

IP: -
Collaborators: Jaume Reventós Puigjaner, Maria Buti Ferret, Xavier Martínez Gómez, Teresa Soriano Sánchez, Israel Molina Romero, Eulàlia Pérez Esquirol, Mònica Sabaté Gallego, Maria Urquizu Padilla
Funding agency: Instituto de Salud Carlos III
Funding: 150645
Reference: EC08/00250
Duration: 01/01/2009 - 31/12/2012

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Variabilidad de la región codificante de la proteina de la capsida viral del virus de la hepatitis B y su relación con el curso de la infección y la respuesta a tratamiento antivirales

IP: -
Collaborators: Maria Buti Ferret
Funding agency: Instituto de Salud Carlos III
Funding: 56265
Reference: PI061512
Duration: 01/01/2007 - 30/12/2009

Related news

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Julia Moltó Cuesta

Julia Moltó Cuesta

Read more
Yann Bertolani

Yann Bertolani

Read more
Inés Carolina Balón  Llerena

Inés Carolina Balón Llerena

Administration and Management
Molecular Medical Imaging
Read more
Elida Teresa Mercado Santis

Elida Teresa Mercado Santis

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.